SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (1531)4/12/1998 12:48:00 AM
From: scaram(o)uche  Read Replies (2) of 1762
 
Maurice:

I *am* interested in CLTR, IDPH, and TCLN. Have owned IDPH on at least a couple of occasions and CLTR once.

You lost me with "It
isn't that I don't think CD20 MAbs won't be ineffective"

I don't understand what you are trying to say. I think that's a quadruple negative, and that you've broken my old record. ;-)

Cancernet doesn't list all trials..... and, it is my understanding that GNE is testing Rituxan in additional B cell malignancies. From the recent IDPH 10-Q.......

"In an effort to identify expanded applications for Rituxan, the Company, in conjunction with Genentech, has authorized over 35
Rituxan post-marketing trials to date. Several of these trials will explore the use of Rituxan in a variety of investigational B-cell
non-Hodgkins lymphoma clinical settings including: (i) combination therapy with widely used chemotherapy regimens for both
low grade and intermediate/high grade disease; (ii) single agent therapy in newly diagnosed, previously untreated low grade
disease; (iii) integration into autologous bone marrow transplant regimens both as an in-vivo purging agent prior to bone
marrow harvest and post-transplant as consolidation therapy; and (iv) treatment of AIDS-related lymphoma. Additionally,
clinical trials will be initiated in other B-cell malignancies and pre-malignant conditions such as chronic lymphocyte leukemia
("CLL"), multiple myeloma and lymphoproliferative disorders associated with solid organ transplant therapies."

and.......

"Ongoing or completed Phase II
studies suggest that Rituxan may also be useful in combination with chemotherapy in low grade or follicular lymphomas, and as
a single agent, or in combination with various chemotherapies, in the treatment of other forms of non-Hodgkin's lymphoma."

Am I missing your point?

Cheers! Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News